Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists.
Mazur W, Kaluza GL, Sapp S, Balog C, Topol EJ, Mark DB, Ellis SG, Kereiakes DJ, Lincoff AM, Kleiman NS. Mazur W, et al. Among authors: topol ej. Am Heart J. 2002 Apr;143(4):594-601. doi: 10.1067/mhj.2002.121519. Am Heart J. 2002. PMID: 11923795 Clinical Trial.
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, Topol EJ. Lincoff AM, et al. Among authors: topol ej. Am Heart J. 2002 May;143(5):847-53. doi: 10.1067/mhj.2002.122173. Am Heart J. 2002. PMID: 12040347 Clinical Trial.
Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
Exaire JE, Butman SM, Ebrahimi R, Kleiman NS, Harrington RA, Schweiger MJ, Bittl JA, Wolski K, Topol EJ, Lincoff AM; REPLACE-2 Investigators. Exaire JE, et al. Among authors: topol ej. Am Heart J. 2006 Jul;152(1):157-63. doi: 10.1016/j.ahj.2005.09.004. Am Heart J. 2006. PMID: 16824849
Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications.
Khan MM, Ellis SG, Aguirre FV, Weisman HF, Wildermann NM, Califf RM, Topol EJ, Kleiman NS. Khan MM, et al. Among authors: topol ej. J Am Coll Cardiol. 1998 Jan;31(1):31-6. doi: 10.1016/s0735-1097(97)00423-3. J Am Coll Cardiol. 1998. PMID: 9426014 Free article. Clinical Trial.
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ. Ghaffari S, et al. Among authors: topol ej. Am J Cardiol. 1998 Jul 1;82(1):7-12. doi: 10.1016/s0002-9149(98)00238-0. Am J Cardiol. 1998. PMID: 9671000 Clinical Trial.
1,220 results